Complex DR-TB Case Management
HAI is testing a tablet-based intervention that could help National Tuberculosis Programs curb drug-resistance, prevent adverse treatment effects, and build tuberculosis capacity among health providers nationwide.
Two common adverse effects of drug resistant-tuberculosis (DR-TB) treatment are irreversible hearing loss and sudden cardiac death. Early identification of these adverse effects and subsequent changes to patient treatment plans are a critical aspect of curbing TB drug resistance.
In partnership with the Mozambican National Tuberculosis Program (NTP), HAI is supporting the implementation of internet connected tablets at high volume DR-TB health facilities equipped with SHOEBOX audiometers and SmartHeart ECGs. When hearing loss or heart rhythm changes are detected, these cases are presented by videoconference to a weekly national DR-TB expert clinical conference using the ECHO model.
Through the roll-out of these devices at subnational levels, HAI and Mozambique’s NTP are helping frontline health workers 1) detect adverse side effects that stem from commonly-used DR-TB treatments; and 2) easily access national TB expertise to determine individualized treatment plans for these complex patient cases.
This novel method serves as an initial test to determine whether National Tuberculosis Programs in other countries could adopt the intervention and ensure that these life-saving services reach the most vulnerable DR-TB patients.
Want to dig a little deeper?
|Pilot of weekly ECHO model videoconferencing system in Mozambique to review complex drug-resistant TB cases||Abstract, 50th World Conference on Lung Health, 2019, Hyderabad, India|
|Proof of concept: integrated tablet-based hearing and ECG testing for Mozambican patients with drug-resistant TB||Abstract, 50th World Conference on Lung Health, 2019, Hyderabad, India|
|Harnessing systems integration: multi-device connectivity in Mozambique||Abstract, 49th Union World Conference on Lung Health, 2018, The Hague, The Netherlands|
|The experience of developing an MDR-TB ECHO programme in the country of Mozambique||Abstract, 49th Union World Conference on Lung Health, 2018, The Hague, The Netherlands|
[2018-2020] Optimizing the safety of drug resistant-TB treatment with mobile audiometry and ECG testing to prevent complications.
This project receives funding support from the Stop TB Partnership.
[2017-2018] Improving Diagnostic, Linkage to Care, and Routing Reporting for TB, MDR/RR-TB and XDR-TB Patients in Mozambique.
This project received funding support from the Stop TB Partnership.
[2015-2018] Strengthening the HIV/MDR-TB Diagnostic and Care Cascade in Mozambique.
This project received funding support from the National Institute of Allergy and Infectious Disease of the National Institutes of Health under award number 30AI027757-28, via a subagreement from the University of Washington.
Check out similar projects
Learn More About:
Stand with HAI
Stand with HAI
When you support Health Alliance International, you take a stand for a more equitable and respectful model of global health. Your donation not only helps us expand our reach, it is an investment in our shared values of health equity and solidarity.
Join the Alliance
Our alliance is made up of supporters, partners, staff, and volunteers who share our commitment to universal access to quality health care. Just like a health system, every person plays a role in keeping us working toward this ultimate goal. Will you join us?
The kind of change we seek requires sustained action. Whether you want to engage in HAI's advocacy work or help spread HAI's mission and model, we rely on our friends and supporters to stand beside us when we stand up for equity in global health.